A small float helped amplify the stock’s swing, turning its IPO into a test of investor sentiment.

The drug developer has no approved products or revenue yet, but the IPO could extend its cash runway by nearly six years.

Some studios are betting on blockbuster ambitions, while others are sticking to lower-risk models that keep returns predictable.

SenseTime co-founder Wang Xiaogang discusses the complexity of embodied intelligence through the lens of ACE Robotics.

The railway platform already controls China’s largest travel user base, giving it a natural advantage if it expands further into hotels and tourism.

The new brand targets young male riders seeking speed, handling, and a stronger sense of identity.

The listing will test investor appetite for decision intelligence as the AI narrative reaches a high point.

The move reflects pressure to lower costs and compete across broader price bands.

Expanding overseas takes more than equipment, capital, and speed.

Three millennia after the Cairo toe, replacement tech is moving from prosthetics and transplants toward a broader theory of aging intervention.